Nacystelyn is under clinical development by Galephar Pharmaceutical Research and currently in Phase II for Acne Vulgaris. According to GlobalData, Phase II drugs for Acne Vulgaris have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nacystelyn’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nacystelyn overview
Nacystelyn is under development for chronic obstructive pulmonary disease (COPD) and recalcitrant acne vulgaris. It is a dry powder administered through inhalation and oral routes. It was also under development for the treatment of cystic fibrosis. It is a lysine salt of N-acetylcysteine.
See Also:
Galephar Pharmaceutical Research overview
Galephar Pharmaceutical Research is a company dedicated to the improvement of galenic preparations using the most advanced technology in the world. The company is headquartered in Puerto Rico, the US.
For a complete picture of Nacystelyn’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
